Tianeptine

Illegal to produce, supply, or import under the Psychoactive Substances Act 2016,³⁸ which came into effect on May 26, 2016.³⁸ The Act does not criminalize personal possession but prohibits all commercial activity.citation needed

Tianeptine is not approved by the Food and Drug Administration for any medical use in the United States. Under the Federal Food, Drug, and Cosmetic Act, a new drug may not be introduced or delivered for introduction into interstate commerce unless an approved application is effective; FDA states that some companies are illegally marketing and selling tianeptine products to consumers. Tianeptine does not appear in the current federal controlled-substance schedules in 21 CFR Part 1308.

Classified as a Schedule III controlled substance since 2010.⁹ Possession, distribution, and production without authorization is prohibited.citation needed

Tianeptine and its esters are listed in Anlage 1 of the Arzneimittelverschreibungsverordnung. Medicinal products that are or contain listed substances may be dispensed only on a medical, dental, or veterinary prescription, unless the regulation provides otherwise. The rule regulates dispensing of medicinal products and does not itself make possession generally contingent on holding a prescription.

The TİTCK green-prescription list names STABLON 12,5 MG 60 TABLET and tianeptine. The list is dated 28 August 2026, but the PDF gives no revision date, so product availability or later list changes remain uncertain for a particular prescription. TİTCK Genelge 2016/3 says green prescriptions are for psychotropic medicines, allows at most two boxes containing the same active ingredient per green prescription absent the specified specialist report, requires the physician and pharmacist fields, and says prescriptions outside the published lists are not accepted and medicines are not dispensed. A valid green prescription therefore permits controlled medicinal dispensing; pure tianeptine is not established as an NPS or categorically prohibited substance. An official Ministry of Health hospital green-psychotropic list revised 30 July 2025 did not contain tianeptine or Stablon, but it is a hospital medication list rather than TİTCK's master green-prescription list and its omission does not itself repeal the TİTCK list; current market availability remains unresolved. TCK Art. 188(6) extends Arts. 188(1)-(3) to a substance only when it produces narcotic/stimulant effects and its production is officially permitted or sale requires an authorized physician prescription. If a court finds those conditions met, Art. 188(3) provides at least 10 years' imprisonment and 1,000-20,000 days' judicial fine for unauthorized in-country selling, offering, giving, dispatching, transporting, storing, buying, accepting or possessing, while Art. 188(1) provides 20-30 years and 2,000-20,000 days for unauthorized manufacture/import/export. Separately, TCK Art. 191(1) provides 2-5 years for buying, accepting, possessing or using a narcotic/stimulant substance for personal use, with the five-year deferred-prosecution and supervised-release framework in Arts. 191(2)-(3). Those criminal provisions are conditional, and no tianeptine-specific judicial classification is established; ordinary possession of a lawfully dispensed green-prescription medicine does not automatically carry those penalties. Arts. 188 and 191 remained unchanged through the official TBMM 7576 record of 19 March 2026.

Legal to possess without any license or prescription. Not scheduled under federal controlled substances legislation.

The official current Swedish narcotics schedule does not list tianeptine, and the current harmful-goods appendix does not list it either, so pure tianeptine is unscheduled rather than a controlled narcotic. Läkemedelsverket's official Läkemedelsfakta service covers all approved and registered medicines and substances in Sweden. It lists no approved, registered, deregistered or temporarily withdrawn tianeptin product, and the regulator's substance autocomplete lists no entries for tianeptin, tianeptine, Stablon or CAS 72797-41-2. Sweden has no identified ordinary prescription tianeptine treatment or approved or registered product. An unapproved medicine may be supplied only through a granted licence application, and no tianeptine licence is established. The Narcotics Penal Act penalties apply to narcotics; because tianeptine is not scheduled as a narcotic, those penalties do not apply to possession of pure tianeptine. Product-specific medicine, import, or other rules may still apply, especially to a product containing other substances.

BetmVV-EDI's current Art. 1-2 framework makes the controlled-substance lists in Annexes 1-6 operative; the complete 13 March 2026 text contains no Tianeptine or Tianeptin entry (it does contain the distinct substance Amineptin). Swissmedic's authorised-medicines tables are updated monthly and reflect its current database; the authorised-human-medicines spreadsheet dated 31 July 2026 contains no tianeptine, tianeptine sodium, Tianeptin or Stablon match. Swissmedic assigns dispensing category A, B, D or E to a specific medicinal product when deciding its authorisation (VAM Art. 40), so an unlisted active substance has no standalone Swiss prescription category. No authorised Swiss tianeptine product is listed. HMG Art. 9 requires a ready-to-use medicine to be Swissmedic-authorised before marketing, while allowing specified pharmacy-compounded Formula magistralis products made for a person on a physician's prescription; this exception is not an OTC classification. Because tianeptine is not a controlled substance on the BetmVV-EDI schedules, BetmG Arts. 19/19a controlled-narcotics possession penalties do not apply to ordinary tianeptine possession. If a tianeptine-containing product is marketed, imported, prescribed or used as an unauthorised medicine, HMG Art. 86(1)(a) provides up to three years' imprisonment or a monetary penalty for intentional conduct, and Art. 87 provides up to CHF 50,000 for specified other offences (including own-use/freely sold cases); applicability depends on the product and conduct.